The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.
April 24th 2024
A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.
Scientists Identify Mechanism of Action of Potential Psoriasis Therapy
March 12th 2015Researchers in Germany have figured out the process by which interleukin 4 (IL-4) inhibits inflammation, pointing the way toward a possible treatment for psoriasis, psoriatic arthritis, and other autoimmune diseases.
Adding Topical Corticosteroids to a Regimen of Etanercept in Patients with Plaque Psoriasis
February 13th 2015The addition of a topical corticosteroid to once-weekly etanercept produces similar outcomes among patients with moderate to severe plaque psoriasis as a regimen of twice weekly etanercept at the same dose.
Plaque Psoriasis: Switching Biologics Effective, Study Finds
Researchers have recently shown that switching from one biological agent to another could potentially prove effective for patients with plaque psoriasis when the initial treatment agent elicits insufficient response.
FDA Approves New Psoriasis Drug
The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx/Novartis) for adults with moderate to severe plaque psoriasis. The European Commission approved the same drug on Jan. 19. Its active ingredient is an antibody that binds to interleukin-17A and interferes with inflammation. The binding prevents that protein from triggering the inflammatory response that results in psoriasis patches.
Study Shows Positive Outcomes with Ixekizumab for the Treatment of Plaque Psoriasis
December 3rd 2014Researchers report that patients diagnosed with moderate to severe plaque psoriasis who were treated with ixekizumab, an investigational anti-interleukin-17A monoclonal antibody, have maintained a favorable clinical response over a year-long course of treatment.
Researchers Report Positive Results for Brodalumab for Patients with Plaque Psoriasis
Amgen and AstraZeneca recently announced AMAGINE-2TM, a pivotal, multi-arm Phase 3 clinical trial, met all primary endpoints for brodalumab, an experimental drug designed for moderate to severe plaque psoriasis treatment.
Plaque Psoriasis Drug Candidate Shows Positive Top-Line Results in First of Two Phase III Studies
October 31st 2014Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
FDA Approves Celgene's PDE4 Inhibitor Otezla for the Treatment of Plaque Psoriasis in Adults
September 23rd 2014Otezla (apremilast) is an oral, selective phosphodiesterase 4 (PDE4) inhibitor for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.
The National Psoriasis Foundation Announces Ambitious New Programs and Initiatives
August 21st 2014The National Psoriasis Foundation (NPF) recently announced a number of new programs and a five-year strategic mission for the organization with initiatives that are designed to increase research and uncover new treatments for all forms of psoriasis and psoriatic disease.
Topical Treatments Show Some Benefit for Plaque Psoriasis Patients
As research continues to be done to find the most efficient treatment for patients with plaque psoriasis a study was recently published looking at how the inclusion of topical corticosteroids can benefit the care provided.
Recognition of Methotrexate Toxicity Key for Patient Treatment
For more than 70 years methotrexate has been a popular tool in the prescription toolkit of doctors around the world. However, a recent case report by a team from the United Kingdom showed how important it is for prescribing doctors to also keep a close eye on some of the well-known adverse events associated with the medication.